<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04529655</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00021286</org_study_id>
    <nct_id>NCT04529655</nct_id>
  </id_info>
  <brief_title>Digital Capillary Refill for Monitoring of Sepsis</brief_title>
  <official_title>Digital Capillary Refill for Monitoring of Sepsis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Observational study for monitoring of capillary refill time in sepsis&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an observational studying assessing changes in capillary refill time over the course&#xD;
      of sepsis treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 12, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Blood lactate Level</measure>
    <time_frame>during procedure</time_frame>
    <description>Correlation of Capillary refill to blood lactate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vasoactive</measure>
    <time_frame>24 hours</time_frame>
    <description>Correlation of capillary refill to need for vasoactive medications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>28 day hospital mortality</measure>
    <time_frame>28 days</time_frame>
    <description>Correlation of initial capillary refill time to 28 day hospital mortality</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>Sepsis</arm_group_label>
    <description>Patients admitted to the ICU with sepsis will be enrolled and monitored at time sequential time points during their treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Capillary Refill Assessment</intervention_name>
    <description>Device to quantify capillary refill time</description>
    <arm_group_label>Sepsis</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adults admitted to the ICU, ED or inpatient floor with sepsis defined as a concern for an&#xD;
        infection with either hemodynamic or respiratory organ failure on intravenous antibiotics&#xD;
        will be eligible.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Clinical evidence of a known or suspected infection and orders written for&#xD;
             administration of IV antibiotics&#xD;
&#xD;
          2. Hypotension as defined by the need for any vasopressor (and 1 liter of fluid already&#xD;
             administered) OR respiratory failure defined by assisted ventilation (includes&#xD;
             mechanical ventilation and BIPAP), CPAP, or greater than or equal to 6 liters/minute&#xD;
             of supplemental oxygen&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. No consent/inability to obtain consent from the participant or a legally authorized&#xD;
             representative&#xD;
&#xD;
          2. Diagnosis of cirrhosis by medical chart review&#xD;
&#xD;
          3. Liver transplant recipient&#xD;
&#xD;
          4. AST or ALT greater than five times upper limit of normal&#xD;
&#xD;
          5. Diagnosis of ongoing chronic alcohol use disorder/abuse by chart review; if medical&#xD;
             record unclear, use Appendix F&#xD;
&#xD;
          6. Clinical diagnosis of diabetic ketoacidosis or other condition such as profound&#xD;
             hypoglycemia that requires hourly blood glucose monitoring&#xD;
&#xD;
          7. Hypersensitivity to Acetaminophen or Vitamin C&#xD;
&#xD;
          8. Patient, surrogate or physician not committed to full support (Exception: a patient&#xD;
             will not be excluded if he/she would receive all supportive care except for attempts&#xD;
             at resuscitation from cardiac arrest)&#xD;
&#xD;
          9. Home assisted ventilation (via tracheotomy or noninvasive) except for CPAP/BIPAP used&#xD;
             only for sleep-disordered breathing&#xD;
&#xD;
         10. Current active kidney stone&#xD;
&#xD;
         11. Known history of oxalate kidney stones or history of oxalate nephropathy&#xD;
&#xD;
         12. Kidney transplant recipient&#xD;
&#xD;
         13. Use of home oxygen for chronic cardiopulmonary disease&#xD;
&#xD;
         14. Moribund patient not expected to survive 24 hours&#xD;
&#xD;
         15. Underlying malignancy or other condition with estimated life expectancy of less than 1&#xD;
             month&#xD;
&#xD;
         16. Pregnant woman, woman of childbearing potential without a documented negative urine or&#xD;
             serum pregnancy test during the current hospitalization, or woman who is breast&#xD;
             feeding&#xD;
&#xD;
         17. Prisoner&#xD;
&#xD;
         18. Enrollment in another critical care based pharmacologic interventional trial&#xD;
&#xD;
         19. Treating team unwilling to enroll because of intended use of Acetaminophen or Vitamin&#xD;
             C&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Sheridan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Sheridan, MD</last_name>
    <phone>503-494-1691</phone>
    <email>sheridda@ohsu.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>OHSU</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Sheridan, MD MCR</last_name>
      <phone>503-494-1691</phone>
      <email>sheridda@ohsu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Matt Hansen, MD MCR</last_name>
      <email>hansemat@ohsu.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 24, 2020</study_first_submitted>
  <study_first_submitted_qc>August 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2020</study_first_posted>
  <last_update_submitted>August 26, 2020</last_update_submitted>
  <last_update_submitted_qc>August 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Dr. David Sheridan</investigator_full_name>
    <investigator_title>Assistant Professor of Emergency Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

